Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 26, Issue 11-12, 2013, Pages 1093-1097

  Iwabuchi, Atsushi ^a   Kamoda, Tomohiro ^a   Saito, Makoto ^a   Nozue, Hiroki ^b   Izumi, Isho ^c   Hirano, Takeki ^d   Sumazaki, Ryo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^c Ibaraki Children's Hospital   (Japan)

^d Hirano Children's Clinic   (Japan)

Author keywords

Adiponectin; CD26; Dipeptidyl peptidase 4; Type 1 diabetes mellitus

Indexed keywords

ADIPONECTIN; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FLUOROMETRY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL PEPTIDASE 4; FEMALE; HUMANS; MALE;

EID: 84888093441     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2013-0122     Document Type: Article

References (24)

1. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64.
2. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
3. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-16.
4. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011;28:1176-81.
5. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9.
6. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, Alizadeh BZ, Saha MT, et al. Association of immune mediators at diagnosis of type 1 diabetes with later clinical remission. Diabet Med 2007;24:512-20.
7. Imagawa A, Hanafusa T, Itoh N, Waguri M, Yamamoto K, et al. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset type I (insulin-dependent) diabetes mellitus. Diabetologia 1999;42:574-8.
8. Fleischer B. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J Immunol 1987;138:1346-50.
9. Heike M, Mobius U, Knuth A, Meuer S, Meyer zum Buschenfelde KH. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol 1988;74:431-4.
10. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998;161:55-7.
11. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60:1917-25.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999:257;79-83.
13. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
14. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
15. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52: 239-43.
16. Pereira RI, Snell-Bergeon JK, Erickson C, Schauer IE, Bergman BC, et al. Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clin Endocrinol Metab 2012;97:E642-7.
17. Matheeussen V, Lambeir AM, Jungraithmayr W, Gomez N, Mc Entee K, et al. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 2012;413: 456-62.
18. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72.
19. Varga T, Somogyi A, Barna G, Wichmann B, Nagy G, et al. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol Oncol Res 2011;17: 925-30.
20. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-6.
21. Celi F, Bini V, Papi F, Santilli E, Castellani MS, et al. Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabet Med 2006;23:660-5.
22. Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, et al. Serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol 2007;157:481-9.
23. Barnes MM, Curran-Everett D, Hamman RF, Maahs D, Mayer-Davis EJ, et al. Determinants of adiponectin levels in young people with type 1 diabetes. Diabet Med 2008;25:365-9.
24. Kirino Y, Sei M, Kawazoe K, Minakuchi K, Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2012;59:949-53.